Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $550.0 million.

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

This week, Viking Therapeutics reported positive results from phase 2 trial of VK2735 in patients with obesity or overweight patients with a comorbidity. The company is raising $350M, but already had cash, cash equivalents and marketable securities of $362M at year-end 2023. Despite raising funds that would allow Viking Therapeutics to fund phase 3 work of VK2735 itself, the company is a potential buyout target.

Viking Therapeutics: VK2735 Data Supports A Buyout

Bitwise Bitcoin ETP Trust

iShares Russell 2000 ETF

NVIDIA

AT&T

The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.

Beyond the "Mag 7": 3 Risk-On Market Forces

Viking Therapeutics' Phase II VENTURE trial of VK2735 shows statistically significant decreases in body weight, positioning it as a potential best-in-class therapy for obesity. VK2735 demonstrates promising efficacy and tolerability, potentially surpassing competitors such as semaglutide and tirzepatide. The positive outcomes from the trial support continued clinical development, with a Phase IIb trial likely as the next step.

Viking Therapeutics: Impressive Obesity Data Puts VK2735 As The Lead Asset (Rating Upgrade)

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. Viking also intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock.

Viking Therapeutics Announces Proposed Public Offering of Common Stock

Viking Therapeutics Inc.'s stock soared 120% Tuesday to a record high, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that it's developing in both injectable and oral form as a treatment for obesity and diabetes.

Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze

CRISPR Therapeutics

Vertex Pharmaceuticals

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.

3 Biotech Stocks Bound to Blast Off By 2029

Viking Therapeutics Inc (NASDAQ:VKTX) stock is skyrocketing today, after the biotech's experimental obesity drug helped achieve "significant" weight loss in a mid-stage study.

Biotech Stock Soars on New Weight-Loss Drug Results

Viking Therapeutics (NASDAQ: VKTX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced positive clinical trial results. These results come from its Phase 2 VENTURE study of VK2735.

Why Is Viking Therapeutics (VKTX) Stock Up 96% Today?

Viking Therapeutics (NASDAQ:VKTX) Inc shares skyrocketed almost 80% on Tuesday morning after the firm unveiled positive results from a trial of its VK2735 weight loss drug. Patients receiving the treatment saw “statistically significant reductions in mean body weight” after a 13-week phase 2 trial, Viking updated on Tuesday.

Viking Therapeutics soars on positive weight-loss drug results

Viking Therapeutics Inc (NASDAQ: VKTX) more than doubled on Tuesday after reporting positive results of a trial involving its weight-loss drug. Viking's GLP-1 significantly reduces weight VK2735 helped participants lose 14.7% of their body weight in thirteen weeks in a Phase 2 trial.

Viking Therapeutics stock doubles on weight-loss drug trial results

Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics.

Viking Therapeutics stock jumps 80% after positive weight loss drug trial results

Viking Therapeutics soared on positive phase two results for its weight-loss treatment. Eli Lilly and Novo Nordisk fell.

Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results

Patients see ‘significant' reductions in body weight during a study of a weight-loss drug developed by Viking Therapeutics, the company says.

Viking Therapeutics Stock Surges 100% on Positive Weight-Loss Drug Trial

Viking Therapeutics said on Tuesday its experimental drug to treat obesity helped achieve "significant" weight loss in a mid-stage study.

Viking Therapeutics' weight-loss drug succeeds in mid-stage study

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed  VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Viking Therapeutics (VKTX) stock price has silently emerged as one of the best-performing companies in Wall Street this year. It jumped by over 14% on Friday and is up by 1.20% in the pre-market session as investors predict that it could be acquired.

What's going on with the Viking Therapeutics (VKTX) stock price?

Arcellx

ADC Therapeutics

Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.

The 3 Biotech Stocks That Could Make Your February Unforgettable

Amgen

AstraZeneca

DexCom

Eli Lilly

Novo Nordisk

Pfizer

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Viking Therapeutics Inc.'s stock soared 17% to a record high on Thursday, after the company said it expects data from early and mid-stage trials of its weight-loss drug as soon as the first quarter, moving the timeline up from the first half.

Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze

Intellia Therapeutics

With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Call Transcript

Conference call scheduled for 4:30 p.m. ET today Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Expected in 1Q24 Histology Results for Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 1H24 Results for Phase 1 Trial of Oral VK2735 Expected in 1Q24 Strong Year-End Cash Position of $362 Million SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

United Rentals

V.F.

Verizon

Vizsla Silver Corp

Westamerica Bancorp

Walgreens

W. P. Carey

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 9 of this series includes Verizon Communications, V.F. Corp, Vizsla Silver, Walgreens Boots Alliance and W. P. Carey, among others.

News for Viking Therapeutics Stock (VKTX)